CMBA
PLX icon

C.M. Bidwell & Associates’s Protalix BioTherapeutics PLX Stock Holding History

C.M. Bidwell & Associates’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-236
Closed -$512 – 534
2026
Q1 		$512 Buy
+236
New +$586 ﹤0.01% 466

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

C.M. Bidwell & Associates's PLX Position: Q2 2026 in Review

C.M. Bidwell & Associates sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 236 shares — an estimated $512 sold.

C.M. Bidwell & Associates first reported a position in PLX in Q1 2026 and held it in 1 quarter. The position peaked at $512 in Q1 2026. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • C.M. Bidwell & Associates reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 236 Protalix BioTherapeutics shares in Q2 2026, an estimated $512.
  • C.M. Bidwell & Associates first reported a position in Protalix BioTherapeutics in Q1 2026 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Protalix BioTherapeutics position peaked at $512 in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.